Una puesta al día fundamental | 25 MAY 21

Hiperuricemia, gota y enfermedades asociadas

Conceptos actuales sobre ventajas y desventajas de la intervención terapéutica.
Autor/a: Claudio Borghi, Enrico Agabiti-Rosei, Richard J. Johnson, Josep Redon y otros. European Journal of Internal Medicine 80 (2020) 1–11.
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

[1] Becker MA. Hyperuricemia editor In: Lang F, editor. Encyclopedia of molecular mechanisms  of diseaseBerlin, Heidelberg: Springer Berlin Heidelberg; 2009. p. 956.

[2] Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin

Rheumatol 2014;26:186–91.

[3] Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237–47.

[4] Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009- 10. PLoS ONE 2012;7:e50046.

[5] Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout prevalence: nutrition and Health Survey in Taiwan from 1993–1996 to 2005-2008.

Asia Pac J Clin Nutr 2 11;20:301–8.

[6] Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7–13.

[7] Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 2008;35:1859–64.

[8] Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 2013;72:694–700.

[9] Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007- 2008. Arthritis Rheum 2011;63:3136–41.

[10] Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J 1973;1:449–51.

[11] Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

Hypertension 2003;41:1183–90.

[12] Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. Semin Nephrol 2011;31:410–9.

[13] Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci 2014;18:1295–306.

[14] Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA, et al. Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med

1987;147:645–9.

[15] Paul BJ, Anoopkumar K, Krishnan V. Asymptomatic hyperuricemia: is it time t intervene? Clin Rheumatol 2017;36:2637–44.

[16] Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005;25:39–42.

[17] Baillie JK, Bates MG, Thompson AA, Waring WS, Partridge RW, Schnopp MF, et al. Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude. Chest 2007;131:1473–8.

[18] Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009;5:e1000504.

[19] Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010;3:523–30.

[20] Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Cicerchi C, Kanbay M, Roncal-Jimenez CA, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 2012;287:40732–44.

[21] Woods HF, Eggleston LV, Krebs HA. The cause of hepatic accumulation of fructose 1-phosphate on fructose loading. Biochem J 1970;119:501–10.

[22] Maxwell SR, Thomason H, Sandler D, Leguen C, Baxter MA, Thorpe GH, et al. Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1997;27:484–90.

[23] Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase- Hypertension 2003;41:1287–93.

[24] Mustard JF, Murphy EA, Ogryzlo MA, Smythe HA. Blood coagulation and platelet economy in subjects with primary gout. Can Med Assoc J 1963;89:1207–11.

[25] Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991;266:8604–8.

[26] Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 2010;28:1234–42.

[27] Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008;295:F1134–41.

[28] Sanchez-Lozada LG, Tapia E, Lopez-Molina R, Nepomuceno T, Soto V, Avila-Casado C, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 2007;292:F1238–44.

[29] Cicerchi C, Li N, Kratzer J, Garcia G, Roncal-Jimenez CA, Tanabe K, et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J 2014;28:3339–50.

[30] Lanaspa MA, Cicerchi C, Garcia G, Li N, Roncal-Jimenez CA, Rivard CJ, et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS ONE 2012;7:e48801.

[31] Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, Li N, Roncal-Jimenez CA, Ishimoto T, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS ONE 2012;7:e47948.

[32] Felici C, Ciari I, Terzuoli L, Porcelli B, Setacci C, Giubbolini M, et al. Purine catabolism in advanced carotid artery plaque. Nucleosides Nucleotides Nucleic Acids 2006;25:1291–4.

[33] Wang S, Shu Z, Tao Q, Yu C, Zhan S, Li L. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology (Carlton) 2011;16:767–76.

[34] Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457–64.

[35] Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hiperuricemia and gout. PLoS ONE 2013;8:e56546.

[36] Cho J, Kim C, Kang DR, Park JB. Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: k-MetS Study. Medicine (Baltimore) 2016;95:e4177.

[37] Cicero AF, Rosticci M, Fogacci F, Grandi E, D'Addato S, Borghi C. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur J Intern Med 2017;37:38–42.

[38] Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study. Int J Cardiol 2016;218:83–8.

[39] Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, Ohya Y, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 2004;27:835–41.

[40] Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102–10.

[41] Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS ONE 2014;9:e114259.

[42] Martin AC, Brown MA. Could uric acid have a pathogenic role in pre-eclampsia? Nat Rev Nephrol 2010;6:744–8.

[43] Thangaratinam S, Ismail KM, Sharp S, Coomarasamy A, Khan KS. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006;113:369–78.

[44] Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003;42:247–52.

[45] Boyle JA, McKiddie M, Buchanan KD, Jasani MGH, Jackson IM, Buchanan WW. Dietes mellitus and gout. Blood sugar and plasma insulin responses to oral glucosa in normal weight, overweight, and gouty patients. Ann Rheum Dis 1969;28:374–8.

[46] Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015;33:1729–41.

[47] Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007;120:442–7.

[48] Dai X, Yuan J, Yao P, Yang B, Gui L, Zhang X, et al. Association between serum uric acid and the metabolic syndrome among a middle- and old-age Chinese population. Eur J Epidemiol 2013;28:669–76.

[49] He SJ, Chan C, Xie ZD, Shi D, Hu XB, Li HY, et al. The relationship between serum uric acid and metabolic syndrome in premenopausal and postmenopausal women in the Jinchang Cohort. Gynecol Endocrinol 2017;33:141–4.

[50] Nejatinamini S, Ataie-Jafari A, Qorbani M, Nikoohemat S, Kelishadi R, Asayesh H, et al. Association between serum uric acid level and metabolic syndrome components. J Diabetes Metab Disord 2015;14:70.

[51] Oda E. Serum uric acid is an independent predictor of metabolic syndrome in Japanese health screening population. Heart Vessels 2014;29:496–503.

[52] Tian Y, Chen K, Xie Z, Fang Y, Wang H, Nie Y, et al. The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study. BMC Cardiovasc Disord 2015;15:66.

[53] Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabolism 2008;57:845–52.

[54] Liu Z, Que S, Zhou L, Zheng S. Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies. Sci Rep 2015;5:14325.

[55] Sun D, Li S, Zhang X, Fernandez C, Chen W, Srinivasan SR, et al. Uric acid is associated with metabolic syndrome in children and adults in a community: the Bogalusa Heart Study. PLoS ONE 2014;9:e89696.

[56] Sun HL, Pei D, Lue KH, Chen YL. Uric acid levels can  predict metabolicef olescents: a 10-year longitudinal study. PLoS ONE 2015;10:e0143786.

[57] Elizalde-Barrera CI, Estrada-Garcia T, Lozano-Nuevo JJ, Garro-Almendaro AK, Lopez-Saucedo C, Rubio-Guerra AF. Serum uric acid levels are associated with homeostasis model assessment in obese nondiabetic patients: HOMA and uric acid. Ther Adv Endocrinol Metab 2017;8:141–6.

[58] Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009;32:1737–42.

[59] Marotta T, Liccardo M, Schettini F, Verde F, Ferrara AL. Association of hiperuricemia with conventional cardiovascular risk factors in elderly patients. J Clin Hypertens 2015;17:27–32.

[60] Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE 2013;8:e56864.

[61] Sluijs I, Holmes MV, van der Schouw YT, Beulens JW, Asselbergs FW, Huerta JM,

et al. A mendelian randomization study of circulating uric acid and type 2 diabetes. Diabetes 2015;64:3028–36.

[62] Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 2000;10:136–43.

[63] Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005;2:e76.

[64] Borghi C, Rodriguez-Artalejo F, De Backer G, Dallongeville J, Medina J, Guallar E, et al. The association between blood pressure and lipid levels in Europe: European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice. J Hypertens 2016;34:2155–63.

[65] Sinan Deveci O, Kabakci G, Okutucu S, Tulumen E, Aksoy H, Baris Kaya E, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract 2010;64:900–7.

[66] Chao TF, Hung CL, Chen SJ, Wang KL, Chen TJ, Lin YJ, et al. The Association between hyperuricemia, left atrial size and new-onset atrial fibrillation. Int J Cardiol 2013;168:4027–32.

[67] Liu Y, Tan N, Chen J, Zhou Y, Chen L, Chen S, et al. The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine. Clinics (Sao Paulo) 2013;68:19–25.

[68] Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study. Stroke 2006;37:1503–7.

[69] Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail 2009;2:556–62.

[70] Cicero AF, Salvi P, D'Addato S, Rosticci M, Borghi C. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens 2014;32:57–64.

[71] Li M, Hou W, Zhang X, Hu L, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis 2014;232:265–70.

[72] Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2014;16:15–24.

[73] Okazaki H, Shirakabe A, Kobayashi N, Hata N, Shinada T, Matsushita M, et al. Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. Heart Vessels 2017;32:436–45.

[74] Piepoli MF, Salvioni E, Corra U, Doni F, Bonomi A, La Gioia R, et al. Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group. Eur J Intern Med 2020;72:47–52.

[75] Shimizu T, Yoshihisa A, Kanno Y, Takiguchi M, Sato A, Miura S, et al. Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction. Am J Physiol Heart Circ Physiol 2015;309:H1123–9.

[76] Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, et al. Elevated serum uric acid levels are associated with diastolic ysfunction in patients with dilated cardiomyopathy. Am Heart J 2002;143:1107–11.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022